Lasa Supergenerics Limited (BOM:540702)
5.39
0.00 (0.00%)
At close: Oct 5, 2026
Lasa Supergenerics Revenue
Lasa Supergenerics had revenue of 13.25M INR in the quarter ending June 30, 2026, a decrease of -93.42%. This brings the company's revenue in the last twelve months to 65.20M, down -95.23% year-over-year. In the fiscal year ending March 31, 2026, Lasa Supergenerics had annual revenue of 252.74M, down -82.60%.
Revenue (ttm)
65.20M
Revenue Growth
-95.23%
P/S Ratio
4.09
Revenue / Employee
7.24M
Employees
9
Market Cap
266.54M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 252.74M | -1.20B | -82.60% |
| Mar 31, 2025 | 1.45B | 407.95M | 39.06% |
| Mar 31, 2024 | 1.04B | -259.96M | -19.93% |
| Mar 31, 2023 | 1.30B | -66.97M | -4.88% |
| Mar 31, 2022 | 1.37B | -652.53M | -32.24% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valiant Laboratories | 3.06B |
| Amanta Healthcare | 2.91B |
| Balaxi Pharmaceuticals | 2.80B |
| Bafna Pharmaceuticals | 1.43B |
| Alpa Laboratories | 1.11B |
| Par Drugs and Chemicals | 1.09B |
| Vaishali Pharma | 1.08B |
| Brooks Laboratories | 831.87M |